Key result
Intravenous glycoprotein IIb/IIIa receptor inhibitors are superior to placebo in managing non-ST elevation acute myocardial infarction, whereas oral formulations are ineffective for long-term use.
Why the study?
Do glycoprotein IIb/IIIa receptor antagonists reduce ischemic complications in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Do glycoprotein IIb/IIIa receptor antagonists reduce ischemic complications in patients with acute coronary syndrome or undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Intravenous glycoprotein IIb/IIIa receptor antagonists are effective in reducing ischemic events in non-ST elevation acute myocardial infarction, while oral formulations lack long-term efficacy.
The integrin glycoprotein IIb/IIIa receptor is the final common pathway to platelet aggregation. Administration of glycoprotein IIb/IIIa receptor antagonists reduces acute ischemic complications following plaque fissuring or rupture. Research on this subject was initially limited to patients undergoing percutaneous coronary intervention. Further studies evaluating the role of glycoprotein IIb/IIIa receptor antagonists in patients with non-ST segment elevation acute coronary syndrome have shown benefit of these drugs in reducing adverse cardiac events and death. Intravenous glycoprotein IIb/IIIa receptor inhibitors (abciximab, tirofiban, and eptifibatide) given in combination with traditional regimens are superior to placebo in management of non-ST elevation acute myocardial infarction. Oral glycoprotein IIb/IIIa receptor inhibitors (orbofiban, sibrafiban, and xemilofiban) are not effective in reducing ischemic events when used on a long-term basis after acute coronary syndrome. Pharmacokinetics, efficacy, and safety of glycoprotein IIb/IIIa receptor antagonists are elaborated.
No takes yet. Share an insight, caveat, or question.
Gowda et al. (2004) conducted a review in Acute coronary syndrome. Glycoprotein IIb/IIIa receptor antagonists vs. Placebo was evaluated. Intravenous glycoprotein IIb/IIIa receptor inhibitors are superior to placebo in managing non-ST elevation acute myocardial infarction, whereas oral formulations are ineffective for long-term use.
Synapse has enriched 10 related papers. Consider them for comparative context: